Primary astrocytes retrovirally transduced with a tyrosine hydroxylase transgene driven by a glial-specific promoter elicit behavioral recovery in experimental parkinsonism

Journal of Neuroscience Research

Volumn 59, Issue 1, 2000, Pages 39-46

  Cortez, Natividad ^a   Trejo, Francisco ^a   Vergara, Paula ^a   Segovia, José ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Gene therapy; Glial fibrillary acidic protein; Promoter; Transplant

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; GLIAL FIBRILLARY ACIDIC PROTEIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CONTROLLED STUDY; GENE ACTIVITY; GENE THERAPY; MALE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROMOTER REGION; RAT; TRANSCRIPTION REGULATION; TRANSGENE;

ANIMALS; ASTROCYTES; CELL CULTURE TECHNIQUES; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; MALE; PARKINSONIAN DISORDERS; PROMOTER REGIONS (GENETICS); RATS; RATS, WISTAR; RETROVIRIDAE; TRANSGENES; TYROSINE 3-MONOOXYGENASE;

EID: 0033959027     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(20000101)59:1<39::AID-JNR6>3.0.CO;2-N     Document Type: Article

References (51)

1. Bacci A. Verderio C, Pravettoni E, Matteoli M. 1999. The role of glial cells in synaptic function. Phil Trans R Soc Lond B 354:403-409.
2. Barker JE, Bolanos JP, Land JM, Clark J, Heales SJR. 1996. Glutathione protects astrocytes from peroxynitrite-mediated mitochondrial damage: implications for neuronal/astrocytic trafficking and neurodegeneration. Dev Neurosci 18:391-396.
3. Besnard F, Brenner M, Nakatani Y, Chao R, Purohit HJ, Freese E. 1991. Multiple interacting sites regulate astrocyte-specific transcription of the human gene for glial fibrillary acidic protein. J Biol Chem 266:18877-18883.
4. Brenner M, Messing A. 1996. GFAP transgenic mice. Methods: Companion Meth Enzymol 10:351-364.
5. Brenner M, Kisseberth WC, Su Y, Messing A. 1994. GFAP promoter directs astrocyte-specitic expression in transgenic mice. J Neurosci 14: 1030-1037.
6. Choi-Lundberg DL, Bohn MC. 1995. Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. Dev Brain Res 85:80-88.
7. Chiu SL, Kriegler S. 1994. Neurotransmitter-mediated signaling between axons and glial cells. Glia 11:191-200.
8. Cunningham LA, Short MP, Breakefield X, Bohn MC. 1994. Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rodent model of Parkinson's disease. Brain Res 658:219-231.
9. de la Monte SM, Wells SE, Hedley-Whyte T, Growdon JH. 1989. Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. Ann Neural 26:309-320.
10. Diaz-Barriga F, Hernandez JM, Carrizales L, Dominguez MC, Yañez L, Palmer E, Saborio JL. 1989. Interactions of cadmium with actin micro-filaments. Toxicol In Vitro 3:277-284.
11. Dunnet SB, Kendall AL, Watts C, Torres EM. 1997. Neuronal cell transplantation for Parkinson's and Huntington's diseases. Br Med Bull 53: 757-776.
12. Eddelston M, Mucke L. 1993. Molecular profile of reactive astrocytes: implications for their role in neurological disease. Neuroscience 54:15-36.
13. Eng LF, Ghirnikar RS. 1994. GFAP and astrogliosis. Brain Pathol 4:229-237.
14. Forno LS, DeLanney LE, Irwin I, Di Monte D, Langston JW. 1992. Astrocytes and Parkinson's disease. Prog Brain Res 94:429-436.
15. Galou M, Pournin S. Ensergueix D, Ridet J-L, Tchelingerian J-L, Loussouarn L, Privat A, Babinet C, Dupouey P. 1994. Normal and pathological expression of GFAP promoter elements in transgenic mice. Glia 12:281-293.
16. Glowinski J, Marin P, Tence M, Stella N, Giaume C, Premont J. 1994. Glial receptors and their intervention in astrocyto-astrocytic and astrocyto-neuronal interactions. Glia 11:201-208.
17. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, Olanow CW. 1999. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disase. Arch Neurol 56: 179-187.
18. Horellou P, Mallet J. 1997. Gene therapy for Parkinson's disease. Mol Neurohiol 15:241-250.
19. Hurtig HI. 1997. Problems with current pharmacologic treatment of Parkinson's disease. Exp Neurol 144:10-16.
20. Johnson WB, Ruppe MD, Rockenstein EM, Price J, Sarthy VP, Verderber LC, Mucke L. 1995. Indicator expression directed by regulatory sequences of the glial fibrillary acidic protein (GFAP) gene: in vivo comparison of distinct GFAP-LacZ transgenes. Glia 13:174-184.
21. Juorio AV, Li X-M, Walz W, Paterson IA. 1993. Decarboxylation of L-dopa by cultured mouse astrocytes. Brain Res 626:306-309.
22. Kopin IJ. 1993. The pharmacology of Parkinson's disease therapy: an update. Annu Rev Pharmacol Toxicol 32:467-495.
23. Lamouroux A, Faucon-Biguet N, Samolyk D, Privat A, Salomon JC, Pujol JF, Mallet J. 1982. Identification of cDNA clones coding for rat tyrosine hydroxylase antigen. Proc Natl Acad Sci USA 79:3881-3885.
24. Lin Q, Cunningham LA, Epstein LG, Pechan PA, Short MP, Fleet C, Bohn MC. 1997. Human fetal astrocytes as an ex vivo gene therapy vehicle for delivering biologically active nerve growth factor. Hum Gene Ther 8:331-339.
25. Ljumberg MC, Stern G, Wilkin GP. 1999. Survival of genetically engineered, adult-derived rat astrocytes grafted into the 6-hydroxydopamine lesioned adult rat striatum. Brain Res 816:29-37.
26. Lundberg C, Horellou P. Mallet J, Bjorklund A. 1996. Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Exp Neurol 139:39-53.
27. Markowitz D, Goff S, Bank A. 1988. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 62:1120-1124.
28. Miller AD, Rosman GJ. 1989. Improved retroviral vectors for gene transfer and expression. BioTechniques 7:980-990.
29. Muller DPR. 1997. Neurological disease. Adv Pharmacol 38:574-577.
30. Palmer TD, Rosman GJ, Osborne WRA, Miller AD. 1991. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 88:1330-1334.
31. Price J, Turner D, Cepko C. 1987. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA 84:156-160.
32. Ridet J-L, Corti O, Pencalet P, Hanoun N, Hamon, M, Philippon J, Mallet J. 1999. Toward autologous ex vivo gene therapy for the central nervous system with human adult astrocytes. Hum Gene Ther 10:271-280.
33. 67) and glial fibrillary acidic protein immunoreactivities in C6 cells. Neurosci Lett 191:9-12.
34. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning. A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
35. Scharfmann R, Axelrod JH, Verma IM. 1991. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci USA 88:4626-4630.
36. Segovia J, Garcia-Munoz M. 1987. Changes in the activity of GAD in the basal ganglia of the rat after striatal dopaminergic denervation. Neuropharmacology 26;1449-1451.
37. Segovia J, Meloni R. Gale K. 1989. Effect of dopaminergic denervation and transplant-derived reinnervation on a marker of striatal GABAergic function. Brain Res 493:185-189.
38. Segovia J, Armstrong DA, Benzing WC, Hornby PJ. 1991. Striatal glutamic acid decarboxylase immunoreactivity is increased after dopaminergic deafferentation: densitometric analysis. Neurosci Lett 122:252-256.
39. 67) and increases the expression of an astroglial marker (GFAP) in C6 cells. J Neurochem 63:1218-1225.
40. Segovia J, Vergara P, Brenner M. 1998a. Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental Parkinsonism. Gene Ther 5:1650-1655.
41. Segovia J, Vergara P, Brenner M. 1998b. Differentiation-dependent expression of transgenes in engineered astrocyte cell lines. Neurosci Lett 242:172-176.
42. Snyder EY, Senut M-C. 1997. The use of nonneuronal cells for gene delivery. Neurobiol Dis 4: 69-102.
43. Tacconi MT. 1998. Neuronal death: is there a role for astrocytes? Neurochem Res 23:759-765.
44. Tornatore C, Baker-Cairns B, Yadid G, Hamilton R, Meyers K, Atwood W, Cummins A, Tanner V, Major E. 1996. Expression of tyrosine hydroxylase in an immortalized human fetal astrocyte cell line; in vitro characterization and engraftment into the rodent striatum. Cell Transpl 5:145-163.
45. Trejo F, Vergara P, Brenner M, Segovia J. 1999a. Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene. Life Sci 65: 483-491.
46. Trejo F, Vergara P, Brenner M, Segovia J. 1999b. Biosynthetic capacity of C6 cells engineered with a glial fibrillary acidic protein-tyrosine hydroxylase transgene. Med Sci Res 27: 423-425.
47. Tsai MJ, Lee EHY. 1996. Characterization of L-dopa transport in cultured rat and mouse astrocytes. J Neurosci Res 43:490-495.
48. Vilijn M-H, Vaysse PJ-J, Zukin RS, Kessler JA. 1988. Expression of preproenkephalin mRNA by cultured astrocytes. Proc Natl Acad Sci USA 85:6551-6555.
49. Wolff JA, Fisher LJ, Xu L, Jinnah HA, Langlais PJ, Iuvone PM, O'Malley KL, Rosenberg MB, Shimohama S, Friedmann T, Gage FH. 1989. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci USA 86:9011-9014.
50. Wszolek ZK, Pfeiffer RF, Bhatt MH, Schelper RL, Cordes M, Snow BJ, Rodnitzky RL, Wolters EC, Arwert F, Calne DB. 1992. Rapidly progressive autosomal dominant Parkinsonism and dementia with pallido-ponto-nigral degeneration. Ann Neurol 32:312-320.
51. Yoshimoto Y, Lin Q, Collier TJ, Frim DM, Breakefield XO, Bohn MC. 1995. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Res 691:25-36.